Area of research
Physiology · Psychiatry and Mental health
Research interest
Research interests include Alzheimer's disease research and treatments, Dementia and Cognitive Impairment Research, Functional Brain Connectivity Studies, and Neuroinflammation and Neurodegeneration Mechanisms.
Glial reactivity correlates with synaptic dysfunction across aging and Alzheimer’s disease
Amyloid beta and tau are associated with the dual effect of neuroinflammation on neurodegeneration
Microglia modulate Aβ-dependent astrocyte reactivity in Alzheimer’s disease
<i>APOE</i> ɛ4 carriership determines a faster plasma p‐tau217 progression in Aβ‐positive individuals
Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer’s disease pathology
Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer’s disease
Equivalence of plasma p‐tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease
Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies
<i>APOE</i> ε4 associates with microglial activation independently of Aβ plaques and tau tangles
Neuropsychiatric Symptoms and Microglial Activation in Patients with Alzheimer Disease
Plasma p‐tau231 and p‐tau217 inform on tau tangles aggregation in cognitively impaired individuals
Sex-specific modulation of amyloid-β on tau phosphorylation underlies faster tangle accumulation in females
APOEε4 potentiates amyloid β effects on longitudinal tau pathology
Potential Utility of Plasma P-Tau and Neurofilament Light Chain as Surrogate Biomarkers for Preventive Clinical Trials
Biomarker modeling of Alzheimer’s disease using PET-based Braak staging
Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography
Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease
Association of locus coeruleus integrity with Braak stage and neuropsychiatric symptom severity in Alzheimer’s disease
Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET
CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals
Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum
Microglial activation and tau propagate jointly across Braak stages
Association of plasma P-tau181 with memory decline in non-demented adults
Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative
Mild behavioral impairment is associated with β‐amyloid but not tau or neurodegeneration in cognitively intact elderly individuals